Other medication classes, including DPP-4 inhibitors; insulin (glargine); alpha-glucosidase inhibitors; glinides; D2-dopamine agonists; GLP-1 agonist; and sulfonylurea are neutral to heart failure outcomes. The gene discussed is GLP1R; the disease is heart failure.